[10] [11] NICE recommends Mounjaro for adults with type 2 diabetes when: It is used according to the recommendations for GLP-1 receptor agonists in NICE guideline NG28 on type 2 diabetes in adults The person has a BMI of at least 35 kg/m (adjusted to 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds) and specific psychological or medical problems associated with obesity, or The person has a BMI lower than 35 kg/m (adjusted as above), and insulin treatment would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities In line with NG28, treatment should only be continued if there is a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and weight loss of at least 3% of initial body weight after 6 months)
These are two different tools
Considering GLP-1R expression on the vagal nerve, it has been proposed that GLP-1RAs affect weight loss via gut-to-brain communication
Effectiveness : (5/5) Arguably more effective than BPC-157 for muscle and tendon injuries
The 12mg dose, 8mg dose, and different dosing schedules all showed superior results compared to other drugs
Watch for unusual bruising, blood in urine or stool, nosebleeds that don't stop within 10 minutes, bleeding gums, or heavy menstrual bleeding
